Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Holdings Lowered by Pitcairn Co.

Pitcairn Co. trimmed its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 21.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,342 shares of the biopharmaceutical company’s stock after selling 2,242 shares during the quarter. Pitcairn Co.’s holdings in Ultragenyx Pharmaceutical were worth $351,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of RARE. Smartleaf Asset Management LLC boosted its position in Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 493 shares during the period. Human Investing LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter worth approximately $42,000. Van ECK Associates Corp increased its position in Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 273 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth $83,000. Finally, Nomura Asset Management Co. Ltd. acquired a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $93,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 1,785 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the transaction, the chief financial officer now directly owns 106,169 shares in the company, valued at $4,289,227.60. This trade represents a 1.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Emil D. Kakkis sold 25,000 shares of the company’s stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $42.48, for a total transaction of $1,062,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,158,985 shares of the company’s stock, valued at approximately $91,713,682.80. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 124,643 shares of company stock worth $5,256,268. 5.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have commented on RARE. Cantor Fitzgerald restated an “overweight” rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. JPMorgan Chase & Co. increased their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an “overweight” rating in a research report on Thursday, March 27th. Wells Fargo & Company boosted their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Wedbush reiterated a “neutral” rating and set a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus price target of $92.79.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $32.43 on Monday. The company’s fifty day moving average price is $40.83 and its 200-day moving average price is $45.93. The company has a market capitalization of $3.04 billion, a price-to-earnings ratio of -5.12 and a beta of 0.61. Ultragenyx Pharmaceutical Inc. has a one year low of $32.07 and a one year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The firm had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.